Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition

• DOI: 10.14341/dm12802
• Publication Date: 2022-09-01T14:02:07Z
• Authors: Ivan I. Dedov; Marina V. Shestakova; Alexander Yu. May...; Natalya G. Mokrys...; Olga K. Vikulova; Gagik R. Galstyan; Tamara L. Kuraeva; Valentina A. Pete...; Olga M. Smirnova; Elena G. Starostina; Elena V. Surkova; Olga Y. Sukhareva; Alla Y. Tokmakova; Minara S. Shamkha...; Ivona Renata Jare...; Ekaterina V. Arte...; Diana D. Beshlieva; Olga N. Bondarenko; Natalya N. Volevodz; Irina S. Gomova; Olga R. Grigoryan; Zera N. Dzhemilova; Roza M. Esayan; Liudmila I. Ibrag...; Viktor Y. Kalashn...; Irina V. Kononenko; Dmitry N. Laptev; Dmitry V. Lipatov; Olga G. Melnikova; Margarina S. Mikhina; Marina S. Michurova; Oleg G. Motovilin; Tatiana V. Nikonova; Roman V. Rozhivanov; Igor A. Sklyanik; Ekaterina A. Shes...
• Keywords: Diabetology

Dear Colleagues! We are glad to present the 10th Edition (revised) of Standards Specialized Diabetes Care. These evidence-based guidelines were designed standardize and facilitate diabetes care in all regions Russian Federation. The updated on regular basis incorporate new data relevant recommendations from national international clinical societies, including World Health Organization Guidelines (WHO, 2011, 2013), International Federation (IDF, 2012, European Association for Study (EASD 2018, 2019), American (ADA, 2019, 2021), Clinical Endocrinologists (AACE, 2020, Society Pediatric Adolescent (ISPAD, 2018) (RAE, 2019). Current edition “Standards” also integrates results completed randomized trials (ADVANCE, ACCORD, VADT, UKPDS, SAVOR, TECOS, LEADER, EXAMINE, ELIXA, SUSTAIN, DEVOTE, EMPA-REG OUTCOME, CANVAS, DECLARE, CARMELINA, REWIND, CREDENCE, CAROLINA, DAPA-CKD, DAPA-HF, EMPEROR-Reduced trial, VERIFY, VERTIS CV, PIONEER, etc.), as well findings studies mellitus (DM), conducted close partnership with a number hospitals. Latest indicates that prevalence DM world increased during last decade more than two-fold, reaching some 537 million patients by end 2021. According current estimation Federation, 643 will be suffering 2030 784 2045. Like many other countries, experiences sharp rise DM. Federal Register, there at least 4 871 863 this country 01.01.2021 (3,34% population) 92,3% (4 498 826)–Type 2 DM, 5,6% (271 468)–Type 1 2,1% (101 569)–other types 9 729 women gestational However, these underestimates real quantity patients, because they consider only registered cases. Results epidemiological study (NATION) confirmed 54% Type diagnosed. So Russia is 10 (about 7% population). This great long-term problem, lot not diagnosed, so don’t receive any treatment have high risk vascular complications. Severe consequences global pandemic include its complications: nephropathy, retinopathy, coronary, cerebral peripheral disease. conditions responsible majority cases diabetes-related disability death. In сurrent “Standards”: New goals glycemic control continuous glucose monitoring (time range, below range above variability) given. It features stratification newly diagnosed diabetes. personalization choice antidiabetic agents, it taken into account certain situations (the presence atherosclerotic cardiovascular diseases their factors, chronic heart failure, kidney disease, obesity, hypoglycemia) classes hypoglycemic agents (or individual drugs) proven advantages. Indications use disease expanded. Information about insulin pump therapy added. Recommendations vaccination An algorithm replacing preparations others text represents consensus absolute experts, achieved through fruitful discussions held meetings forums. intended endocrinologists, primary physicians, pediatricians medical professionals involved Compared previous Care edited Dedov I.I., Shestakova M.V., ­Mayorov A.Yu., edition, Moscow, 2021 (signed printing 10.09.2021) changes been made. On behalf Working Group